Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal filtrate
- Development stage
- Phase 3
- Lead developer
- Weill Cornell Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral Gavage (in Animal Models), Colonoscopy Or Nasogastric Tube In Humans
01
Overview
Fecal filtrate is a preparation derived from human or animal feces that has been processed to remove intact bacteria, retaining only bacterial debris, metabolites, bacteriophages (viruses that infect bacteria), and other soluble components. It is used experimentally as an alternative to traditional fecal microbiota transplant (FMT) for the treatment of recurrent *Clostridioides difficile* infection (CDI) and other gastrointestinal disorders. The mechanism of action is not fully understood but may involve restoration of gut microbial balance through the transfer of non-living microbial products such as bacteriophages and metabolites like short-chain fatty acids. Recent studies suggest that these components can modulate the gut microbiome and host immune response even in the absence of live bacteria[1][2][4].
- Other names
- fecal bacteria-free suspensionsterile fecal filtrate
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on fecal filtrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal filtrate.